Skip to content

2026 ACHONDROPLASIA & SKELETAL DYSPLASIA RESEARCH CONFERENCE • ORLANDO, FL

FRIDAY, SEPT 11 - SUNDAY, SEPT 13
The Chandler Project
  • ABOUTExpand
    • MISSION
    • FOUNDER’S STORY
  • COMMUNITYExpand
    • Friends of Chandler
    • RARE-X
    • PICNIC HEALTH
    • THE MIGHTY
  • CONDITIONSExpand
    • ACHONDROPLASIA
    • HYPOCHONDROPLASIA
    • PSEUDOACHON.
    • SEDC
  • PHARMACHONExpand
    • Nurse Vic’s Notes
  • RESEARCHExpand
    • NEWS
    • STUDIES & TRIALS
    • Treatments & PipelinesExpand
      • BioMarin Pharmaceutical
      • QED Therapeutics
      • Ascendis Pharma
      • Tyra Biosciences
      • SANOFI
      • INNOSKEL
      • PFIZER (NULL)
  • CONTACT
Instagram Facebook Facebook Group Linkedin Email
The Chandler Project

CHANGE IN HEIGHT

  • Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life
    Achondroplasia · Vosoritide

    Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life

    Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of lifeSavarirayan, Ravi et al.Genetics in Medicine, Volume 26,…

    Read More Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of lifeContinue

  • Vosoritide therapy in children with achondroplasia aged 3?59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial
    Treating Achondroplasia · Vosoritide

    Vosoritide therapy in children with achondroplasia aged 3?59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial

    Source: The Lancet Child & Adolescent Health Authors: Prof Ravi Savarirayan, MD • Prof William R Wilcox, MD • Prof Paul Harmatz, MD • John Phillips III, MD • Lynda…

    Read More Vosoritide therapy in children with achondroplasia aged 3?59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trialContinue

Copyright © 2026 · The Chandler Project · Hello You Designs

translate ?
Scroll to top
Loading Comments...
  • ABOUT
    • MISSION
    • FOUNDER’S STORY
  • COMMUNITY
    • Friends of Chandler
    • RARE-X
    • PICNIC HEALTH
    • THE MIGHTY
  • CONDITIONS
    • ACHONDROPLASIA
    • HYPOCHONDROPLASIA
    • PSEUDOACHON.
    • SEDC
  • PHARMACHON
    • Nurse Vic’s Notes
  • RESEARCH
    • NEWS
    • STUDIES & TRIALS
    • Treatments & Pipelines
      • BioMarin Pharmaceutical
      • QED Therapeutics
      • Ascendis Pharma
      • Tyra Biosciences
      • SANOFI
      • INNOSKEL
      • PFIZER (NULL)
  • CONTACT
Search